These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 37407731)
1. Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial. Rauch-Kröhnert U; Puccini M; Placzek M; Beyer-Westendorf J; Jakobs K; Friebel J; Hein S; Seidel M; Pieske B; Massberg S; Witzenrath M; Zeiher A; Friede T; Anker SD; Landmesser U Clin Res Cardiol; 2023 Nov; 112(11):1620-1638. PubMed ID: 37407731 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lopes RD; de Barros E Silva PGM; Furtado RHM; Macedo AVS; Bronhara B; Damiani LP; Barbosa LM; de Aveiro Morata J; Ramacciotti E; de Aquino Martins P; de Oliveira AL; Nunes VS; Ritt LEF; Rocha AT; Tramujas L; Santos SV; Diaz DRA; Viana LS; Melro LMG; de Alcântara Chaud MS; Figueiredo EL; Neuenschwander FC; Dracoulakis MDA; Lima RGSD; de Souza Dantas VC; Fernandes ACS; Gebara OCE; Hernandes ME; Queiroz DAR; Veiga VC; Canesin MF; de Faria LM; Feitosa-Filho GS; Gazzana MB; Liporace IL; de Oliveira Twardowsky A; Maia LN; Machado FR; de Matos Soeiro A; Conceição-Souza GE; Armaganijan L; Guimarães PO; Rosa RG; Azevedo LCP; Alexander JH; Avezum A; Cavalcanti AB; Berwanger O; Lancet; 2021 Jun; 397(10291):2253-2263. PubMed ID: 34097856 [TBL] [Abstract][Full Text] [Related]
3. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol. Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R; Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394 [TBL] [Abstract][Full Text] [Related]
4. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial. Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765 [TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Ramacciotti E; Barile Agati L; Calderaro D; Aguiar VCR; Spyropoulos AC; de Oliveira CCC; Lins Dos Santos J; Volpiani GG; Sobreira ML; Joviliano EE; Bohatch Júnior MS; da Fonseca BAL; Ribeiro MS; Dusilek C; Itinose K; Sanches SMV; de Almeida Araujo Ramos K; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; de Menezes Cavalcante BB; Moreira RCR; Chang C; Tafur A; Fareed J; Lopes RD; Lancet; 2022 Jan; 399(10319):50-59. PubMed ID: 34921756 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI; JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959 [TBL] [Abstract][Full Text] [Related]
7. Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial. Busani S; Tosi M; Mighali P; Vandelli P; D'Amico R; Marietta M; Forfori F; Donati A; Cinnella G; De Monte A; Pasero D; Bellani G; Tascini C; Foti G; Ranieri M; Girardis M Trials; 2020 Aug; 21(1):724. PubMed ID: 32807241 [TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial. Lopes RD; de Barros E Silva PGM; Furtado RHM; Macedo AVS; Ramacciotti E; Damini LP; Bronhara B; Cavalcanti AB; Rosa RG; Azevedo LCP; Veiga VC; Machado FR; Ritt LE; Martins PA; Alexander JH; Avezum A; Berwanger O; Am Heart J; 2021 Aug; 238():1-11. PubMed ID: 33891907 [TBL] [Abstract][Full Text] [Related]
9. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial. Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635 [TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial. Piazza G; Spyropoulos AC; Hsia J; Goldin M; Towner WJ; Go AS; Bull TM; Weng S; Lipardi C; Barnathan ES; Bonaca MP; Circulation; 2023 Jun; 147(25):1891-1901. PubMed ID: 37154020 [TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban in Outpatients with Mild or Moderate COVID-19: Rationale and Design of the Study CARE (CARE - Coalition COVID-19 Brazil VIII). Oliveira GBF; Neves PDMM; Oliveira HA; Catarino DGM; Alves LBO; Cavalcanti AB; Rosa RG; Veiga VC; Azevedo LCP; Berwanger O; Lopes RD; Avezum Á Arq Bras Cardiol; 2023 Mar; 120(3):e20220431. PubMed ID: 37018790 [TBL] [Abstract][Full Text] [Related]
13. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Suh E; Spiro TE; Barnathan ES; Raskob GE; N Engl J Med; 2018 Sep; 379(12):1118-1127. PubMed ID: 30145946 [TBL] [Abstract][Full Text] [Related]
15. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism. Robertson L; Yeoh SE; Ramli A Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199 [TBL] [Abstract][Full Text] [Related]
16. Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. Capell WH; Barnathan ES; Piazza G; Spyropoulos AC; Hsia J; Bull S; Lipardi C; Sugarmann C; Suh E; Rao JP; Hiatt WR; Bonaca MP Am Heart J; 2021 May; 235():12-23. PubMed ID: 33577800 [TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. Sholzberg M; Tang GH; Rahhal H; AlHamzah M; Kreuziger LB; Áinle FN; Alomran F; Alayed K; Alsheef M; AlSumait F; Pompilio CE; Sperlich C; Tangri S; Tang T; Jaksa P; Suryanarayan D; Almarshoodi M; Castellucci LA; James PD; Lillicrap D; Carrier M; Beckett A; Colovos C; Jayakar J; Arsenault MP; Wu C; Doyon K; Andreou ER; Dounaevskaia V; Tseng EK; Lim G; Fralick M; Middeldorp S; Lee AYY; Zuo F; da Costa BR; Thorpe KE; Negri EM; Cushman M; Jüni P; BMJ; 2021 Oct; 375():n2400. PubMed ID: 34649864 [TBL] [Abstract][Full Text] [Related]
19. A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial. Sharma A; Sharma C; Raina S; Singh B; Dadhwal DS; Dogra V; Gupta S; Bhandari S; Sood V Trials; 2021 Jul; 22(1):451. PubMed ID: 34266452 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. ; ; ; Lawler PR; Goligher EC; Berger JS; Neal MD; McVerry BJ; Nicolau JC; Gong MN; Carrier M; Rosenson RS; Reynolds HR; Turgeon AF; Escobedo J; Huang DT; Bradbury CA; Houston BL; Kornblith LZ; Kumar A; Kahn SR; Cushman M; McQuilten Z; Slutsky AS; Kim KS; Gordon AC; Kirwan BA; Brooks MM; Higgins AM; Lewis RJ; Lorenzi E; Berry SM; Berry LR; Aday AW; Al-Beidh F; Annane D; Arabi YM; Aryal D; Baumann Kreuziger L; Beane A; Bhimani Z; Bihari S; Billett HH; Bond L; Bonten M; Brunkhorst F; Buxton M; Buzgau A; Castellucci LA; Chekuri S; Chen JT; Cheng AC; Chkhikvadze T; Coiffard B; Costantini TW; de Brouwer S; Derde LPG; Detry MA; Duggal A; Džavík V; Effron MB; Estcourt LJ; Everett BM; Fergusson DA; Fitzgerald M; Fowler RA; Galanaud JP; Galen BT; Gandotra S; García-Madrona S; Girard TD; Godoy LC; Goodman AL; Goossens H; Green C; Greenstein YY; Gross PL; Hamburg NM; Haniffa R; Hanna G; Hanna N; Hegde SM; Hendrickson CM; Hite RD; Hindenburg AA; Hope AA; Horowitz JM; Horvat CM; Hudock K; Hunt BJ; Husain M; Hyzy RC; Iyer VN; Jacobson JR; Jayakumar D; Keller NM; Khan A; Kim Y; Kindzelski AL; King AJ; Knudson MM; Kornblith AE; Krishnan V; Kutcher ME; Laffan MA; Lamontagne F; Le Gal G; Leeper CM; Leifer ES; Lim G; Lima FG; Linstrum K; Litton E; Lopez-Sendon J; Lopez-Sendon Moreno JL; Lother SA; Malhotra S; Marcos M; Saud Marinez A; Marshall JC; Marten N; Matthay MA; McAuley DF; McDonald EG; McGlothlin A; McGuinness SP; Middeldorp S; Montgomery SK; Moore SC; Morillo Guerrero R; Mouncey PR; Murthy S; Nair GB; Nair R; Nichol AD; Nunez-Garcia B; Pandey A; Park PK; Parke RL; Parker JC; Parnia S; Paul JD; Pérez González YS; Pompilio M; Prekker ME; Quigley JG; Rost NS; Rowan K; Santos FO; Santos M; Olombrada Santos M; Satterwhite L; Saunders CT; Schutgens REG; Seymour CW; Siegal DM; Silva DG; Shankar-Hari M; Sheehan JP; Singhal AB; Solvason D; Stanworth SJ; Tritschler T; Turner AM; van Bentum-Puijk W; van de Veerdonk FL; van Diepen S; Vazquez-Grande G; Wahid L; Wareham V; Wells BJ; Widmer RJ; Wilson JG; Yuriditsky E; Zampieri FG; Angus DC; McArthur CJ; Webb SA; Farkouh ME; Hochman JS; Zarychanski R N Engl J Med; 2021 Aug; 385(9):790-802. PubMed ID: 34351721 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]